Alimta 100mg & 500mg Injection

Indication

Treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).

Dosage (summary)

The recommended dose of Pemetrexed is 500 mg/m² administered as an intravenous infusion over 30 minutes on day 1 of each 21-day cycle.

Onset of Action / Duration

The onset of action is typically observed within 2 to 3 weeks after the initiation of treatment.

Special Populations

• Elderly patients may require dose adjustment.
• Patients with renal impairment should have their dose adjusted based on creatinine clearance.

Pregnancy & Breastfeeding

Pemetrexed is contraindicated in pregnancy and breastfeeding due to potential harm to the fetus or infant.

Key Drug Interactions

• Caution is advised when used with NSAIDs, as they may increase the risk of toxicity.
• Concurrent use with other myelosuppressive agents may increase the risk of hematologic toxicity.

Contraindications

• Hypersensitivity to Pemetrexed or any component of the formulation.
• Severe renal impairment (creatinine clearance < 45 mL/min).

Common side effects

• Nausea and vomiting.
• Fatigue.
• Anemia.
• Neutropenia.
• Thrombocytopenia.

Counselling Points

• Advise patients to report any signs of infection, unusual bruising, or bleeding.
• Encourage adequate hydration before and after treatment.
• Discuss the importance of regular blood tests to monitor blood counts.